Usefulness of remote monitor system for adverse events in outpatient receiving cancer chemotherapy for colorectal cancer

Usefulness of remote monitor system for adverse events in outpatient receiving cancer chemotherapy for colorectal cancer - Usefulness of remote monitor system for adverse events in outpatient receiving cancer chemotherapy for colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050348

Enrollment

220

Registered

2023-02-15

Start date

2022-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Remote monitoring group 1) Colorectal cancer 2) Patients who received CapeOX as a postoperative chemotherapy from May 2022 to October 2023 3) 20 age old over 4) Patients who has a smartphone 5) Patients who can use the present remote monitoring system 6) Provided written informed consent Patient diary group 1) Colorectal cancer 2) Patients who received CapeOX as a postoperative chemotherapy from April 2018 to April 2020 3) 20 age old over

Exclusion criteria

Exclusion criteria: Remote monitoring group/Patient diary group 1) Patients with skin syndrome requiring treatment 2) Patients with history of administration of capecitabine 3) Patients deemed inappropriate for the study by the investigator

Design outcomes

Primary

Measure	Time frame
The incidence of Grade >=2 hand-foot syndrome (Relapse-Free survival(RFS))	—

Countries

Japan

Contacts

Public ContactAkio Suzuki

Gifu University Hospital Department of Pharmacy

akio@gifu-u.ac.jp0582307080

Outcome results